Valuation: Tenax Therapeutics, Inc.

Market Cap 756M 665M 617M 568M 1.06B 73.18B 1.08B 7.38B 2.88B 35.69B 2.84B 2.78B 124B P/E 2026 *
-10.5x
P/E 2027 * -10.7x
Enterprise Value 156M 137M 127M 117M 219M 15.07B 223M 1.52B 593M 7.35B 584M 572M 25.51B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day-0.27%
1 week-2.32%
Current month+1.24%
1 month+7.99%
3 months+5.44%
6 months+0.20%
Current year+20.84%
1 week 14
Extreme 14
16.26
1 month 12.41
Extreme 12.41
19.4
Current year 10.25
Extreme 10.25
19.4
1 year 5.78
Extreme 5.78
19.4
3 years 2.77
Extreme 2.77
61.2
5 years 2.77
Extreme 2.77
3,135.04
10 years 2.77
Extreme 2.77
85,120
Manager TitleAgeSince
Chief Executive Officer 52 14/07/2021
Director of Finance/CFO 58 11/05/2026
Chief Tech/Sci/R&D Officer - 21/01/2025
Director TitleAgeSince
Chairman 67 01/06/2021
Director/Board Member 76 25/02/2021
Director/Board Member 69 25/02/2021
Date Insider Type Main position Quantity % Market Cap.
13/7/26 Fiscal year

Chief Executive Officer

17,438 0.0657%
11/5/26 Other

Chief Financial Officer

0 0%
11/5/26 Free

Chief Financial Officer

460,000 2.6748%
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%-2.32%+143.31%-42.46% 756M
+1.08%-5.74%-4.98%+11.68% 46.06B
+3.11%+5.27%+402.57%+627.12% 38.91B
+2.14%+3.27%+11.18%+67.90% 35.57B
+4.13%-2.10%+6.09%-9.68% 33.13B
+1.23%-1.99%-0.05%+30.76% 26.42B
+0.62%-2.37% - - 16.61B
+15.03%+12.30%+38.10%+144.62% 15.08B
-6.32%-4.86%+4.36%+8.04% 14.08B
+1.63%-0.01%+1.25%-29.94% 12.81B
Average +2.23%-2.27%+66.87%+89.78% 23.94B
Weighted average by Cap. +2.44%-2.47%+75.37%+133.41%

Financials

2026 *2027 *
Net sales - -
Net income -79.71M -70.1M -65.13M -59.9M -112M -7.72B -114M -779M -304M -3.77B -299M -293M -13.06B -93.97M -82.64M -76.78M -70.61M -132M -9.1B -135M -918M -358M -4.44B -353M -345M -15.4B
Net Debt -600M -528M -490M -451M -846M -58.11B -861M -5.86B -2.29B -28.34B -2.25B -2.2B -98.32B -
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
24/07/26 USD 14.73 -0.41% 1,050,219
22/07/26 USD 14.79 -5.92% 1,644,589
21/07/26 USD 15.72 +0.26% 1,276,799
20/07/26 USD 15.68 -1.07% 823,154
17/07/26 USD 15.85 +5.11% 808,315
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
14.79USD
Average target price
35.22USD
Spread / Average Target
+138.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock